問卷

TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of General Surgery

Division of Thoracic Surgery

Digestive System Department

MacKay Memorial Hospital

Digestive System Department

Division of Thoracic Surgery

更新時間:2023-09-19

黃文傑
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

11Cases

2022-02-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-09-01 - 2024-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

2017-08-10 - 2021-06-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated12Sites

2015-11-30 - 2026-05-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

黃煦晴
Taipei Veterans General Hospital

Division of Thoracic Medicine

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2022-05-02 - 2023-04-18

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2015-02-25 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting2Sites

Terminated10Sites

2021-09-01 - 2024-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2017-08-10 - 2025-01-09

Phase III

Completed
A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
  • Condition/Disease

    Patients with unresectable, previously untreated advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).

  • Test Drug

    Injection Injection

Participate Sites
12Sites

Recruiting12Sites

2015-11-30 - 2026-05-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2015-02-25 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

1 2